Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage renal disease
2015-000856-16Phase 4Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV) and end-stage kidney disease (ESKD), sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Hemodialysis extraction ratio of dolutegravir. Started Apr 2015; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2015-000856-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000856-16.